MENU 
Close 
GRS Blog
PAST POSTS
Close
China Clears Its First Microarray Platform for in Vitro Diagnostics to Accelerate Personalized Medicine
19/2/2012
This is an interesting article about SFDA's approval in China for the first Microarray Platform for in Vitro Diagnostics.
It's not only a first for the Platform but also moves closer to truly personalised medicine. Affymetrix, Inc views this registration as a significant start to their growth within Asia especially when you consider that the molecular diagnostic market in China is the fastest growing in the world.
Comment by Greer Deal, Director of Global Regulatory Services (GRS)
Past Posts...
Instead of “STEM” perhaps read “STEAM” says Peter Barron, Google’s Head of External Relations
29 February 2012
29 February 2012
China Evening: Cambridge 100 Club Dinner
20 February 2012
20 February 2012
Umbilical cord blood hits the news again
19 February 2012
19 February 2012
China Clears Its First Microarray Platform for in Vitro Diagnostics to Accelerate Personalized Medicine
19 February 2012
19 February 2012
UK: "Regulator under fire on faulty implants" - MHRA's response to The Financial Times
2 February 2012
2 February 2012
Pharma giants joining forces to combat tropical diseases
2 February 2012
2 February 2012
